Literature DB >> 6176643

Identification of the T cell subset that produces human gamma interferon.

J A O'Malley, A Nussbaum-Blumenson, D Sheedy, B J Grossmayer, H Ozer.   

Abstract

Positive and negative selection procedures combined with cytofluorographic analysis and lysis with monoclonal antibodies were utilized to identify the T lymphocyte subset that produces human gamma interferon (gamma-IFN) (formerly referred to as "immune" or "type II" interferon) in response to mitogen stimulation. Lymphocytes were separated on the basis of their Fc receptors for IgG or IgM, their nonreactivity with IgM or IgG antibodies, and their reactivity with the monoclonal antibodies OKT4, OKT8, OKT11a, and OKM1. Isolated T cell subsets were incubated with the gamma-IFN inducer, phytohemagglutinin. Three days after induction, the cell supernatants were harvested and assayed for interferon. The T cell subset that produces gamma-IFN was identified as E rosette positive with the phenotype: T gamma, T non-micro, OKM1+, OKT4-, OKT8- and OKT11a+. gamma-IFN production by cells was resistant to doses of x-irradiation that abrogate mitogen-induced T suppressor function but was highly sensitive to low doses of 4-hydroperoxycyclophosphamide. These data demonstrate that gamma-IFN is produced by the T gamma, OKM1+ lymphocyte subset, but these cells may also require the presence of accessory monocytes for elaboration of gamma-IFN. The anti-proliferative activity of gamma-IFN may be responsible for the previously described suppressor function of this subset, and gamma-IFN production by T gamma cells may distinguish this subset from the suppressor/cytotoxic functions of the OKT8+ subset or the mitogen-induced OKT4+ suppressor.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6176643

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Production of interferon and tumour necrosis factor by cloned human natural cytotoxic lymphocytes and T cells.

Authors:  S E Christmas; A Meager; M Moore
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

2.  Effect of anticancer drugs on the release of interferon gamma in vitro.

Authors:  K Ahmed; P H van der Meide; J L Turk
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Undermethylation of interferon-gamma gene in human T cell lines and normal T lymphocytes.

Authors:  R Fukunaga; M Matsuyama; H Okamura; K Nagata; S Nagata; Y Sokawa
Journal:  Nucleic Acids Res       Date:  1986-06-11       Impact factor: 16.971

4.  Mechanisms of macrophage activation in rheumatoid arthritis: the role of gamma-interferon.

Authors:  M G Ridley; G S Panayi; N S Nicholas; J Murphy
Journal:  Clin Exp Immunol       Date:  1986-03       Impact factor: 4.330

5.  Biosynthetic human interferon treatment of herpetic keratitis.

Authors:  G Smolin
Journal:  Trans Am Ophthalmol Soc       Date:  1983

6.  Factors affecting the autologous mixed lymphocyte reaction in kidney transplantation.

Authors:  L Fuller; C Flaa; D Jaffe; J Strauss; G K Kyriakides; J Miller
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

7.  Decreased expression of human class II antigens on monocytes from patients with acquired immune deficiency syndrome. Increased expression with interferon-gamma.

Authors:  W Heagy; V E Kelley; T B Strom; K Mayer; H M Shapiro; R Mandel; R Finberg
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

8.  The mEPN scheme: an intuitive and flexible graphical system for rendering biological pathways.

Authors:  Tom C Freeman; Sobia Raza; Athanasios Theocharidis; Peter Ghazal
Journal:  BMC Syst Biol       Date:  2010-05-17

9.  In vitro activation of natural killer-like cytotoxicity by specifically in vivo primed T-helper lymphocytes in the rat.

Authors:  V Britten; R A Robins; R W Baldwin
Journal:  Immunology       Date:  1984-05       Impact factor: 7.397

10.  Interferon production in primary immunodeficiencies.

Authors:  P M Matricardi; M R Capobianchi; R Paganelli; J Facchini; M C Sirianni; R Seminara; F Dianzani; F Aiuti
Journal:  J Clin Immunol       Date:  1984-09       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.